In an effort to deliver better patient outcomes while at the same time countering slow market growth and declining profitability, the global healthcare industry has adopted a new business model that shifts its focus from developing blockbuster drugs and building pipelines to business portfolio evolution, according to a report by Deloitte. The industry is also more focused than before on the regulatory landscape, emerging markets and treatment changes outcomes.
The report concludes that the primary drivers behind this shift are expiring patents and generic competition, pricing pressures, heightened regulatory scrutiny, expansion into emerging markets, increasing alliances and acquisitions, and a persistent economic slowdown.
The report also closely examines the current state of the global life sciences industry and the top issues facing stakeholders. It provides a snapshot of activity in a number of geographic markets such as health-care reforms, cost controls, government industry incentives and economic impacts on the industry, as well as the strategies companies may adopt to grow revenue and market share in 2013 and beyond.
The report is available to download from the Deloitte website.